Antisense oligonucleotide (ASO)-based therapies have emerged as a promising frontier in cancer treatment, offering a precise approach to targeting disease-associated proteins at the molecular level. These ASOs hold potential in inhibiting cell signaling pathways implicated in cancer progression, presenting a novel strategy for addressing unmet clinical needs. Through advancements in delivery systems, stability enhancements, and increased specificity, ASOs have shown promise in various disease domains, including oncology. This review focuses on the application of ASOs in targeted cancer therapies, exploring their mechanisms of action, therapeutic efficacy, and clinical prospects.
The rising incidence and mortality of cancer globally have underscored the need for innovative therapeutic approaches. Understanding the genetic alterations driving carcinogenesis has led to the development of molecular targeted therapies. Artificial intelligence is increasingly employed to select molecular targets, utilizing multiomic data to guide strategies for combating cancer cells. Among RNA-based therapies, ASOs have been a focus of investigation for their ability to selectively target specific mRNAs, silencing disease-causing genes. The review delves into the significance of ASOs in cancer treatment, shedding light on their potential impact on precision medicine.
ASOs, composed of short DNA or RNA molecules, are designed to target specific genes and proteins, minimizing off-target effects and maximizing therapeutic efficacy. Chemical modifications have significantly enhanced the stability and effectiveness of ASOs, enabling less frequent dosing and improved intracellular targeting. ASOs have the advantage of penetrating cell membranes to reach non-coding RNA molecules, offering a unique therapeutic approach compared to traditional drugs like monoclonal antibodies. The review provides insights into the current landscape of ASOs as therapeutic agents and summarizes their clinical trials in the context of cancer treatment.
The development of ASO-based therapeutics involves a series of stages, from discovery and preclinical research to clinical trials and regulatory review. Leveraging bioinformatics tools, ASO structures are designed in silico, validated through in vitro and in vivo studies, and optimized for maximal therapeutic effect. Chemical modifications play a crucial role in enhancing ASO stability and targeting specificity. Various delivery systems are employed based on the mechanism of action of the ASO, ranging from systemic administration to local injections or specialized carriers for intracellular targeting.
Advancements in ASO technology have opened new avenues for cancer therapy, with ASOs showing efficacy in inhibiting translation, altering splicing, activating RNase H, and inhibiting microRNA activity. These mechanisms offer precise targeting of disease pathways, presenting a promising approach for personalized cancer treatment. The review highlights the importance of multiomic analyses in understanding cancer biology and guiding the development of targeted therapies. ASOs represent a valuable tool in the evolving landscape of precision oncology, offering novel strategies for combatting cancer at the molecular level.
Key Takeaways:
– ASOs hold promise in cancer therapy by targeting specific genes and proteins with reduced off-target effects.
– Chemical modifications enhance ASO stability and effectiveness, enabling precise molecular targeting.
– Multiomic analyses play a vital role in guiding the development of ASO-based therapies for personalized cancer treatment.
– ASOs can inhibit translation, modulate splicing, activate RNase H, and target microRNA activity, offering diverse mechanisms for cancer therapy.
Tags: drug delivery, lipid nanoparticles, secretion, regulatory, downstream, clinical trials, immunotherapy, bioinformatics, monoclonal antibodies
Read more on pmc.ncbi.nlm.nih.gov